Fate Therapeutics faces a precarious outlook as its reliance on volatile, non-recurring milestone payments has failed to offset the high fixed-cost burden of its proprietary iPSC manufacturing infrastructure. The company's inability to scale revenue, which con...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$0.25+1.4% vs -$0.25 | $2M+55.3% vs $1M |
Q2 2026 May 13, 2026 | -$0.26+10.3% vs -$0.29 | $1M-12.9% vs $1M |
Q1 2026 Feb 26, 2026 | -$0.27+0.0% vs -$0.27 | $1M+2.4% vs $1M |
Q4 2025 Nov 13, 2025 | -$0.27+6.9% vs -$0.29 | $2M+45.3% vs $1M |
What happened Fate Therapeutics, Inc. (NASDAQ: FATE) said the California Institute for Regenerative Medicine awarded it a $15.0 million CLIN2 grant on September 25, 2026. The grant supports RECLAIM-LN, a Phase 2, potentially registrational trial of FT819 in refractory moderate-to-severe systemic lupus erythematosus with lupus nephritis. RECLAIM-LN, also called FT819-201, is a multicenter, open-label, single-arm
$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus Nephritis
SAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disease, today announced that four abstracts from its off-the-shelf CAR T-cell programs have been selected for presentation at the American College of Rheumatology (ACR) Convergence 2026, being held November 6-11 in Orlando, Florida.
SAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced clinical data from its off-the-shelf anti-CD19 CAR T-cell product candidate FT819, and pre-clinical data from its off-the-shelf anti-CD19 and CD38 CAR T-cell product candidate FT839 will be featured at the Congress of Clinical Rheumatology West (CCR – West) meeting, being held in Huntington Beach, CA on September 17-20, 2026.
Benchmark FATE against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Fate Therapeutics, Inc. (FATE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.32 | $270.42M | -2.02 | -51.24% | -2051.08% | -51.84% | — | |
| $55.43 | $5.35B | -8.57 | -89.97% | -3368.72% | -24.39% | — | |
| $12.26 | $1.38B | -3.22 | 16.92% | -672.16% | -57.79% | — | |
| $24.50 | $2.52B | -30.25 | 120.01% | -54.75% | -7.7% | — | |
| $2.62 | $402.07M | -1.46 | 25.39% | -157.32% | -196.63% | — | |
| $2.89 | $804.26M | -3.01 | — | — | -134.49% | — |
Fate Therapeutics, Inc. (FATE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Fate Therapeutics, Inc. (FATE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Jun 15, 2026·SEC
Jun 4, 2026·SEC
Get notified when FATE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Fate Therapeutics, Inc. (FATE) stock FAQ — growth, dividends, profitability & financials explained
Fate Therapeutics, Inc. (FATE) reported $6.5M in revenue for fiscal year 2025. This represents a 455% increase from $1.2M in 2011.
Fate Therapeutics, Inc. (FATE) saw revenue decline by 51.2% over the past year.
Fate Therapeutics, Inc. (FATE) reported a net loss of $126.0M for fiscal year 2025.
Fate Therapeutics, Inc. (FATE) has a return on equity (ROE) of -51.8%. Negative ROE indicates the company is unprofitable.
Fate Therapeutics, Inc. (FATE) had negative free cash flow of $105.7M in fiscal year 2025, likely due to heavy capital investments.
